Moderna Inc. ($MRNA) Stock Forecast: Up 1.7% Today

What is Moderna Inc.?

Moderna, Inc. (MRNA) is a biotechnology company revered for its groundbreaking contributions in mRNA therapeutics, notably including vaccines against COVID-19. The company is actively engaged in pioneering innovative treatments for a range of diseases, placing emphasis on oncology and infectious diseases.

Why is Moderna Inc. going up?

MRNA stock is up 1.7% on Apr 21, 2026 14:44

• Moderna's upward market trajectory can be linked to a sequence of favorable occurrences and disclosures:
• Approval of a dual flu and COVID-19 vaccine targeted at older adults in the EU, demonstrating the company's ongoing success in broadening its product offerings.
• Disclosure of encouraging data during the AACR 2026 annual meeting, particularly regarding the impressive response rates seen with mRNA-4359 in melanoma patients, underscoring the potential of Moderna's treatment methodologies.
• Participation in forthcoming investor conferences, underscoring Moderna's proactive approach to engaging with shareholders and showcasing advancements in mRNA technology.
• The downturn observed in Boston Scientific's stock might have indirectly influenced Moderna's upward trend, as investors potentially redirected their attention to firms within the healthcare sector with more promising growth opportunities.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Moderna lines up melanoma and myeloma data for ASCO in Chicago

Moderna announced that three abstracts on its investigational mRNA therapeutics have been accepted for presentation at the 2026 ASCO Annual Meeting. The presentations include a 5-year update on intismeran plus pembrolizumab in resected melanoma, and two poster presentations covering intismeran autogene as adjuvant therapy in melanoma and mRNA-2808 in multiple myeloma. Moderna will also host a live investor webcast on June 1 to discuss these presentations.

https://www.stocktitan.net/news/MRNA/moderna-announces-data-to-be-presented-at-2026-asco-annual-0fpp3w959zhz.html

Moderna wins EU approval for combined flu, COVID shot for older adults

Moderna has received marketing authorization from the European Commission for its combination vaccine designed to prevent both influenza and COVID-19. This approval is specifically for adults aged 50 years and older. The development marks a significant step in offering a single shot solution for these two respiratory viruses in the older population.

https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-wins-eu-approval-combined-flu-covid-shot-older-adults-2026-04-21/

Boston Scientific stock hits 52-week low at 60.54 USD

Boston Scientific's stock has hit a 52-week low, trading at $60.43, just below its official low of $60.59. Despite a challenging year with a nearly 35% decline, InvestingPro suggests the stock may be undervalued given its prominent position in the Healthcare Equipment & Supplies industry and strong 20% revenue growth. Analysts have issued mixed but generally optimistic updates, adjusting price targets while maintaining Buy or Outperform ratings.

https://www.investing.com/news/company-news/boston-scientific-stock-hits-52week-low-at-6054-usd-93CH-4626446

AACR 2026: Moderna, Revolution, Zymeworks and BeOne showcase new data

The AACR 2026 annual meeting saw new data presented from Moderna, Revolution Medicines, Zymeworks, and BeOne. Moderna's experimental antigen therapy mRNA-4359 showed an 83% overall response rate in melanoma patients when combined with Keytruda. Revolution Medicines updated its Phase 1 data for lung cancer drug zoldonrasib, demonstrating a 52% confirmed ORR and 11.1 months median progression-free survival. Zymeworks presented "encouraging but early" data for zanidatamab in early-stage HER2-positive breast cancer, suggesting it could reduce the need for chemotherapy, while BeOne's Tevimbra combinations in head and neck squamous cell carcinoma did not show added benefit over monotherapy.

https://www.biospace.com/drug-development/aacr-2026-moderna-revolution-zymeworks-and-beone-showcase-new-data

Moderna to Present at Upcoming Conferences in May 2026

Moderna, Inc. has announced its participation in three investor conferences in May 2026: the BofA Securities 2026 Healthcare Conference, the RBC Global Healthcare Conference, and the Berenstein's 32nd Annual Strategic Decisions Conference. Live webcasts of these presentations will be available on Moderna's investor relations website, with replays archived for at least 30 days. The company, a pioneer in mRNA medicine, aims to transform disease treatment and prevention through its technology platform.

https://www.eagletribune.com/region/moderna-to-present-at-upcoming-conferences-in-may-2026/article_8bd2c1fb-ee36-5d6a-a68c-bcc53d91996b.html

Trending Today

Aurora Cannabis Inc. ($ACB) Stock Forecast: Up 6.5% Today

SNDL Inc. ($SNDL) Stock Forecast: Up 5.2% Today

Tilray Inc. ($TLRY) Stock Forecast: Up 14.6% Today

Cronos Group Inc. ($CRON) Stock Forecast: Up 17.2% Today

The Boeing Company ($BA) Stock Forecast: Up 4.0% Today

General Electric Company ($GE) Stock Forecast: Down 5.1% Today

United Continental Holdings Inc. ($UAL) Stock Forecast: Down 7.1% Today

Booking Holdings Inc. ($BKNG) Stock Forecast: Down 5.2% Today

WEX Inc. ($WEX) Stock Forecast: Up 5.0% Today

Riot Platforms, Inc. ($RIOT) Stock Forecast: Up 5.0% Today

Moderna Inc. Price History

02.03.2026 - MRNA Stock was down 5.2%

• Moderna's decline in stock value could be linked to concerns regarding slow enrollment in COVID-19 vaccine trials, mirroring issues observed with Pfizer and BioNTech. This trend suggests potential difficulties in gathering post-marketing data and a waning interest in COVID-19 vaccines.
• The temporary pause in vaccine trial enrollment may have instilled uncertainty among investors concerning the vaccine development timeline and regulatory clearance, resulting in a negative impact on Moderna's stock performance.
• Investor attention appears to be shifting towards other biotech entities such as Allogene Therapeutics, benefiting from positive sector trends and experiencing a rise in stock prices. This redirection of focus and investment away from Moderna potentially contributed to its recent decline.

02.03.2026 - MRNA Stock was down 5.7%

• Moderna's stock experienced a bearish movement today, possibly influenced by:
• Pfizer and BioNTech halting enrollment in a large U.S. COVID-19 vaccine trial due to slow recruitment, reflecting potential challenges and decreased interest in vaccine trials.
• Market sentiment shifting towards Allogene Therapeutics, which is gaining momentum in the biotechnology sector with positive clinical pipeline developments, diverting attention from Moderna.
• Mixed trade ideas and technical analyses on Moderna's stock from traders, indicating uncertainty and varied perspectives on its future movements.
• The bearish trend in Moderna's stock today could be a result of concerns regarding vaccine trial enrollment, competition in the biotech sector, and divergent market analyses, leading to a decline in investor confidence in the short term.

18.02.2026 - MRNA Stock was down 5.1%

• Moderna's stock declined by 3.77% today.
• Institutional selling pressure, specifically with one entity reducing its stake, has impacted the stock causing short-term uncertainty.
• Despite exceeding earnings expectations and receiving positive feedback on its mRNA flu vaccine from regulatory authorities, the stock is facing a downward trend due to conflicting technical indicators and expert opinions.
• Market sentiment towards Moderna remains cautious as worries about potential risks outweigh recent company achievements and progress in precision medicine.

01.03.2026 - MRNA Stock was up 5.3%

• The recent upward trend in Moderna's stock price can be linked to its strategic shift towards oncology research and the development of next-gen respiratory solutions, underscoring a focus on sustained growth opportunities extending beyond the realm of pandemic-related vaccines.
• Investor enthusiasm is likely fueled by Moderna's dedicated efforts in oncology, particularly the promising outcomes in personalized neoantigen therapy for melanoma, signaling positive market responses to the company's diversification.
• Moderna's target of achieving profitability by 2028, backed by a substantial cash reserve and a recent legal settlement, instills further confidence among investors regarding the company's trajectory.
• Noteworthy progress in resolving the ongoing patent dispute with Arbutus Biopharma Corp (ABUS) may have also contributed to the positive momentum of Moderna's stock, as a favorable resolution in legal matters could help alleviate uncertainties for stakeholders.

21.03.2026 - MRNA Stock was up 1.7%

• Moderna's upward market trajectory can be linked to a sequence of favorable occurrences and disclosures:
• Approval of a dual flu and COVID-19 vaccine targeted at older adults in the EU, demonstrating the company's ongoing success in broadening its product offerings.
• Disclosure of encouraging data during the AACR 2026 annual meeting, particularly regarding the impressive response rates seen with mRNA-4359 in melanoma patients, underscoring the potential of Moderna's treatment methodologies.
• Participation in forthcoming investor conferences, underscoring Moderna's proactive approach to engaging with shareholders and showcasing advancements in mRNA technology.
• The downturn observed in Boston Scientific's stock might have indirectly influenced Moderna's upward trend, as investors potentially redirected their attention to firms within the healthcare sector with more promising growth opportunities.

27.02.2026 - MRNA Stock was down 6.0%

• Moderna's stock (MRNA) faced a bearish movement, potentially attributed to profit-taking following a period of strong performance.
• Despite being a key player in the biotech industry and expanding its pipeline, investors may have reacted cautiously to potential challenges in the vaccine market and broader biotech sector.
• The company's shift towards treatments for respiratory viruses, oncology, and rare diseases may not have immediately captured market optimism, contributing to the bearish movement.
• The market's trajectory could also be influenced by general sector trends or broader economic factors impacting investor sentiment towards biotech stocks.

27.02.2026 - MRNA Stock was down 5.1%

• Moderna's stock experienced a significant drop today, possibly influenced by the broader market sentiment affected by the U.S.-Iran conflict and policy deadlines.
• The internal realignment by Vanguard, resulting in 0 reported shares, might have also contributed to the downward pressure on Moderna's stock.
• Despite ongoing growth potential from strategic partnerships and promising pipelines, the stock faced short-term selling pressure, reflecting investor concerns.
• The market's negative reaction to the overall uncertainty and rising oil prices could have led to the decline in Moderna's stock, creating potential buying opportunities for investors eyeing high-quality stocks.

27.02.2026 - MRNA Stock was down 5.2%

• A realignment announcement by Vanguard of 0 MRNA shares might have created uncertainty among investors, leading to a sell-off of Moderna stock.
• The comparison between ImmunityBio and Moderna, highlighting Moderna's broader pipeline and financial stability, could have influenced investors to shift their focus towards ImmunityBio, impacting Moderna's stock price negatively.
• Despite being a leading player in the biotech sector and strategically diversifying its pipeline, Moderna's stock might have faced downward pressure due to concerns about the company's ability to sustain growth beyond its COVID-19 vaccine.
• The potential for significant growth over the next five years for Moderna might not have been enough to offset the immediate bearish sentiment surrounding the stock today.

08.03.2026 - MRNA Stock was up 5.5%

• Moderna's surge in the market may be linked to optimistic views on its international COVID-19 vaccine markets, emphasized by analysts. Expectations of substantial gains from deals like the UK's COVID booster program and future post-pandemic market agreements have spurred investor confidence.
• Despite reduced forecasts for its RSV vaccine, the heightened revenue projections for Moderna's COVID-19 vaccines by analysts at the bank have likely instilled faith in the company's growth prospects among investors.
• The upbeat market reception to Moderna's potential expansion in global markets may have overshadowed the reservations raised by the 'Underperform' rating and $31 price target set by analysts. This hints at a disparity between analyst evaluations and market sentiments.

08.03.2026 - MRNA Stock was up 6.7%

• Moderna saw a significant rise in its stock price following an increase in price target to $35 from $30 by RBC Capital Markets, while maintaining a "Sector Perform" rating.
• This optimistic forecast signifies the market's confidence in Moderna's potential growth within the biotech sector.
• Analyst revisions, including the raised price target, indicate sustained interest and positivity towards Moderna's pipeline and future developments.
• The general positive sentiment towards Moderna may also be influenced by the broader optimistic outlook on biotech firms and healthcare technology progress, driving investor enthusiasm towards innovative solutions such as mRNA-based therapies.

31.02.2026 - MRNA Stock was up 5.3%

• The positive investor sentiment towards the company's strategic shift towards oncology and next-generation therapies is likely the driving force behind the recent bullish movement of the company's stock.
• Favorable data on individualized neoantigen therapy for melanoma and the company's emphasis on cancer drug development are factors contributing to the market's positive response to the company's new direction.
• The selling of shares by an insider at a different company may have indirectly impacted the company's stock positively, potentially leading investors to view the company's strategic pivot more favorably.
• The company's proactive approach to diversifying its portfolio and focusing on innovative therapies appears to have resonated well with investors, leading to the upward movement in its stock price.

15.03.2026 - MRNA Stock was up 7.5%

• Moderna saw strong bullish movement today possibly due to the positive expectations surrounding its upcoming first-quarter 2026 financial results.
• The company's scheduled live conference call and webcast discussing financial results and future plans may have boosted investor confidence.
• Investor interest remains high in the biotech and healthcare sectors, exemplified by Moderna's positive market response in comparison to developments in other companies.
• Moderna's active engagement with investors and market optimism regarding its financial results likely contributed to the bullish movement in its stock price today.